Table 1 Test cohort demographic and biomarker data for all diagnostic groups

Age at LP (years)

62.5 (57–68)

70.0 (68–75)

61.0 (57–66)

65.0 (61–69)

62.0 (57–68)

63.5 (50–67)

% Male

42.3

75.0

60.0

47.1

71.4

46.7

Symptom onset to LP (months)

36 (24–60)

(n = 154)

36 (18.5–48)

36 (24–60)

(n = 44)

36 (24–48)

60 (18–72)

N/A

MMSE

22 (17–25)

(n = 142)

22 (18–28)

(n = 15)

24 (18–27)

(n = 42)

25 (9.5–28)

(n = 8)

27 (16–27)

(n = 7)

30 (30–30)

Duration of follow-up (months)

12 (6–24)

11 (4–29.5)

11 (6–23)

12 (4–24)

23 (11–43)

N/A

Aβ1–42 (pg/mL)

310.5 (218.0–451.5)

357.5 (327.0–490.0)

638.0 (396.0–871.0)

440.0 (308.0–696.0)

767.0 (633.0–859.0)

953.0 (771.0–1199.0)

T-tau (pg/mL)

674.5 (430.0–973.5)

338.5 (185.0–489.0)

289.0 (187.0–389.0)

501.0 (367.0–744.0)

319.0 (229.0–458.0)

303.5 (189.0–402.0)

T-tau/Aβ1–42 ratio

2.3 (1.2–3.7) (n = 154)

0.8 (0.4–1.5)

0.4 (0.3–0.7) (n = 44)

1.1 (0.7–2.1)

0.5 (0.3–0.6)

0.3 (0.2–0.4)

P-tau-181 (pg/L)

86.4 (59.4–111.8) (n = 119)

47.1 (38.1–64.3) (n = 16)

49.2 (37.0–64.0) (n = 39)

62.5 (49.8–100.1) (n = 13)

50.9 (25.5–58.6)

47.8 (39.3–65.4)

(n = 26)

NFL (ng/L)

1191.5 (857.6–1584.0)

(n = 119)

929.6 (839.9–1650.1)

(n = 17)

1788.4 (839.9–3334.6)

(n = 38)

1974.9 (1627.7–3490.5)

(n = 12)

2400.0 (1687.5–3584.7)

(n = 6)

649.0 (515.9–849.5)

YKL-40 (ng/mL)

163 (127–194)(n = 114)

158 (134–186)(n = 16)

163 (135–244)(n = 35)

192 (140–207)(n = 10)

179 (132–256)(n = 5)

111 (93–164)(n = 29)

AβX-38 (ng/L)

1462.0 (1101.4–2025.5)

(n = 117)

1214.2 (840.1–1529.2)

(n = 15)

1306.0 (1106.2–1658.8)

(n = 34)

1653.8 (1251.7–2046.7)

(n = 12)

1751.4 (1442.0–1777.0)

(n = 5)

2183 (1980.8–3058.6)

(n = 29)

AβX-40 (ng/L)

3635.1 (2911.0–4584.4)

(n = 117)

2916.1 (2235.6–3718.2)

(n = 15)

3439.5 (2714.7–4274.9)

(n = 34)

3900.6 (3175.7–4355.6)

(n = 12)

3965.4 (3702.2–4537.6)

(n = 5)

5478.3 (4888.3–7615.2)

(n = 29)

AβX-42 (ng/L)

164.6 (109.1–231.6)

(n = 117)

182.1 (170.9–281.7)

(n = 15)

284.5 (195.2–369.4)

(n = 34)

183.0 (117.4–343.6)

(n = 12)

346.0 (309.9–372.1)

(n = 5)

592.2 (469.7–749.8)

(n = 29)

AβX-42/X-40 ratio

0.043 (0.036–0.053)

(n = 117)

0.055 (0.047–0.089)

(n = 15)

0.083 (0.072–0.094)

(n = 34)

0.052 (0.040–0.087)

(n = 12)

0.087 (0.085–0.093)

(n = 5)

0.107 (0.092–0.114)

(n = 29)

APPα (ng/mL)

348.8 (254.9–532.7)

(n = 119)

218.6 (175.8–368.1)

(n = 16)

270.7 (164.9–328.7)

(n = 37)

374.3 (316.1–467.3)

(n = 12)

379.5 (281.7–479.8)

(n = 5)

426.4 (322.0–654.5)

APPβ (ng/mL)

202.2 (151.2–325.8)

(n = 119)

138.0 (115.0–175.2)

(n = 16)

128.0 (107.4–187.1)

(n = 37)

220.3 (178.8–298.1)

(n = 12)

181.9 (171.4–236.4)

(n = 5)

258.6 (182.0–372.0)